Blog

QSP Modeling for Parkinson’s Disease: Solving the Synthetic Control Challenge in Clinical Trials

QSP modeling for Parkinson’s disease tackles optimized standard-of-care, placebo response, and missing biomarkers. See how…

Certara2026 年 6 月 11 日

Publication

Oxford Academic, Neuro-Oncology Pediatrics – BRAF pub: Growth recovery in patients with BRAF-altered pediatric low-grade glioma following treatment with tovorafenib

This publication reports a pooled retrospective analysis evaluating growth patterns in children with B-Raf proto-oncogene…

Dorottya Gui-Bodnar2026 年 5 月 28 日

Blog

关于临床试验中的 CRFs，您需要知道的一切

Read about the basics of CRFs and eCRF design, why annotated CRFs should be standardized…

Certara2026 年 5 月 22 日

Webinar

Minimize risk when preparing for hepatic impairment studies

Certara2026 年 5 月 12 日

Guide

Designing Drug Development Programs for Reimbursement Success

Download the guide to learn how model-informed drug development, QSP, and MBMA help align with…

Certara2026 年 5 月 7 日

Publication

Population Pharmacodynamic Modeling of Plozasiran for Treatment of Familial Chylomicronemia Syndrome

A newly approved RNA interference (RNAi) therapy lowers harmful triglyceride (TG) levels in patients with…

Certara2026 年 5 月 7 日

Publication

Population Pharmacokinetics and Exposure-Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation

This study evaluated how the leukemia drug ziftomenib behaves in the body and whether different…

Certara2026 年 5 月 7 日

Publication

Population Pharmacokinetic Modeling and Exposure-Response Analyses of Nemtabrutinib in Patients With Hematologic Malignancies

Population pharmacokinetic (PopPK) and exposure-response modeling were used to support the clinical development of nemtabrutinib,…

Certara2026 年 5 月 7 日

Blog

ADC Dose Optimization: Applying Model-Informed Strategies in Development

Explore ADC dose optimization using model-informed strategies to balance efficacy and safety across antibody drug…

Certara2026 年 4 月 22 日

Case Study

How Certara Enabled Fruquintinib FDA Approval for Metastatic Colorectal Cancer

HUTCHMED was preparing a New Drug Application (NDA) submission for FRUZAQLA® (fruquintinib) a drug developed…

Certara2026 年 4 月 7 日

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software

临床试验

QSP Modeling for Parkinson’s Disease: Solving the Synthetic Control Challenge in Clinical Trials

Oxford Academic, Neuro-Oncology Pediatrics – BRAF pub: Growth recovery in patients with BRAF-altered pediatric low-grade glioma following treatment with tovorafenib

关于临床试验中的 CRFs，您需要知道的一切

Minimize risk when preparing for hepatic impairment studies

Designing Drug Development Programs for Reimbursement Success

Population Pharmacodynamic Modeling of Plozasiran for Treatment of Familial Chylomicronemia Syndrome

Population Pharmacokinetics and Exposure-Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation

Population Pharmacokinetic Modeling and Exposure-Response Analyses of Nemtabrutinib in Patients With Hematologic Malignancies

ADC Dose Optimization: Applying Model-Informed Strategies in Development

How Certara Enabled Fruquintinib FDA Approval for Metastatic Colorectal Cancer

订阅时事通讯

快捷链接

解决方案

联系我们